NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched an expanded cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery82, for central nervous system (CNS) biomarker discovery and qualification.
The new assay simultaneously measures 82 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularlyAlzheimer’s, Parkinson’s, multiple sclerosis and ALS diseases.
The launch of csfdiscovery82 demonstrates the acceleration in NextGen Sciences strategy of becoming a leading player in the growing CNS biomarker market.
Read more: Click Here
..Comments for each blog posting are always appreciated.
.. All comments are moderated to reduce SPAM and bad language
